Apply for Exam

  • Certification Blueprint

    ABAI's Certification Blueprint illustrates the expected coverage of topics appearing on the annual Certification and Maintenance of Certification examinations. The percentages (shown below) are to be used as a guideline and are not a definitive representation of examination content. These percentages are regularly monitored by the ABAI Board of Directors with the intent that the examination content will reflect the breadth of medical knowledge essential for competence in allergy and immunology.

    Certification
    Item Classification List % Coverage
    I. Basic Science 35%
    A. Immune mechanisms 15%
    B. Cells Involved in Immune Responses
    (Differentiation, Origin, Reception, Interactions, Secretions)
    10%
    C. Anatomy / Physiology / Pathology 7%
    D. Research Principles 3%
    II. Clinical Science 65%
    A. Hypersensitivity Disorders 31%
    B. Immunological Disorders 12%
    C. Non-Disease Specific Pharmacology / Therapeutics 10%
    D. Specific Diagnostic Modalities 7%
    E. Allergens / Antigens 5%
  • CAP Blueprint
    A. Hypersensitivity Disorders (epidemiology, risk factors, pathogenesis, clinical presentation, diagnosis and differential diagnosis, treatment/management)
    1. Head and neck – Nasal (allergic and non-allergic rhinitis) /sinus (acute and chronic, NP, allergic fungal sinusitis) / ocular
    2. Dermatologic – Eczema / Atopic Dermatitis / Contact Hypersensitivity / Urticaria / Angioedema (hereditary and acquired)
    3. Lung – Asthma and related disorders (occupational diseases, ABPA, hypersensitivity pneumonitis, eosinophilic granulomatous polyangiitis (CSS), COPD, ILD)
    4. Food and Drug Allergy/Hypersensitivity Reactions (not including eosinophilic GI disease)
    5. Anaphylaxis (not food or drug-related) – Idiopathic, exercise, latex, stinging insect / Mastocytosis / Mast cell disorders
    B. Immunological Disorders (epidemiology, risk factors, pathogenesis, clinical presentation, diagnosis and differential diagnosis, treatment/management)
    1. Immune Hypersensitivity Disorders – includes immune complex, autoimmune, and autoinflammatory (febrile) disorders; other aspects of immune-mediated inflammation (e.g., vaccination, immunotherapies for neoplasia)
    2. Immunodeficiencies – including SCID, CID, T cell disorders, Humoral – B cell disorders (hypogammaglobulinemia, antibody deficiencies), phagocytic disorders, complement disorders, and secondary immunodeficiencies
    3. Eosinophilic and Gastrointestinal Disorders – (Eosinophilic gastrointestinal disorders, HES, others)
  • CQE Blueprint
    A. Hypersensitivity Disorders (epidemiology, risk factors, pathogenesis, clinical presentation, diagnosis and differential diagnosis, treatment/management)
    1. Head and neck – Nasal (allergic and non-allergic rhinitis) /sinus (acute and chronic, NP, allergic fungal sinusitis) / ocular
    2. Dermatologic – Eczema / Atopic Dermatitis / Contact Hypersensitivity / Urticaria / Angioedema (hereditary and acquired)
    3. Lung – Asthma and related disorders (occupational diseases, ABPA, hypersensitivity pneumonitis, eosinophilic granulomatous polyangiitis (CSS), COPD, ILD)
    4. Food and Drug Allergy/Hypersensitivity Reactions (not including eosinophilic GI disease)
    5. Anaphylaxis (not food or drug-related) – Idiopathic, exercise, latex, stinging insect / Mastocytosis / Mast cell disorders
    B. Immunological Disorders (epidemiology, risk factors, pathogenesis, clinical presentation, diagnosis and differential diagnosis, treatment/management)
    1. Immune Hypersensitivity Disorders – includes immune complex, autoimmune, and autoinflammatory (febrile) disorders; other aspects of immune-mediated inflammation (e.g., vaccination, immunotherapies for neoplasia)
    2. Immunodeficiencies – including SCID, CID, T cell disorders, Humoral – B cell disorders (hypogammaglobulinemia, antibody deficiencies), phagocytic disorders, complement disorders, and secondary immunodeficiencies
    3. Eosinophilic and Gastrointestinal Disorders – (Eosinophilic gastrointestinal disorders, HES, others)

Updated: October 2019